A Ru free-layer cap provides superior magnetic and magnetotransport properties compared to a Mg free-layer cap. Mg from the Mg free-layer cap is observed to diffuse toward the MgO tunnel barrier upon annealing, degrading both the crystalline quality of the CoFeB and magnetic isolation of the CoFeB free-layer from the CoFeB reference-layer. Lateral variations

in the B distribution within the CoFeB free-layer are observed in the samples with a Ru free-layer cap, which are associated with crystalline and amorphous grains. The B-rich, amorphous grains are found to be depleted in Fe, while the B-poor crystalline grains are slightly Smoothened Agonist enriched in Fe. (C) 2011 American Institute of Physics. [doi :10.1063/1.3583569]“
“As a measure of healthcare cost containment, the total number of vials of entanercept

(25 mg) that can be prescribed for patients with inflammatory arthritis is restricted in Korea. Consequently, attempts to extend the dosing interval while maintaining the efficacy have not been an uncommon clinical practice. The aim of this study was to determine if extended doing interval of etanercept can be effective in patients with ankylosing spondylitis (AS). We performed a retrospective analysis using medical records at a single tertiary hospital. One hundred and nine patients with AS and 79 patients with rheumatoid arthritis (RA) started on etanercept between November 2004 and November 2009 were indentified. Etanercept (25 mg) was started with twice-weekly dosing MK-2206 cost schedule. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), C-reactive protein (CRP), and etanercept dosing interval for BAY 57-1293 mw AS patients at 0, 3, 9, 15, 21 months were reviewed. Dosing interval for RA patients was analyzed for comparison. In AS, mean dosing interval was 4.7 +/- 2.1 days at 3 months and was increased to 12.1 +/- 7.0 days at 21 months. Despite the progressive increase in the dosing interval, the mean BASDAI declined rapidly at 3 months, and continued to decrease over 21 months. Mean CRP declined after 3 months of therapy and remained low thereafter.

In RA, mean dosing interval was 4.0 +/- 1.2 days at 3 months and 5.1 +/- 1.8 days at 21 months. In conclusion, in AS, extended dosing of etanercept can be effective without compromising clinical and laboratory markers of disease activity as measured by BASDAI and CRP, respectively. Tapering of etanercept was less accommodating in RA when compared to AS.”
“Bioassay-guided fractionation of the ethanolic extract of Pterodon emarginatus Vogel stem bark (EtEx) resulted in the isolation and characterization of lupeol and betulin. Their structures were elucidated by spectroscopic methods including IR, (1)H-NMR, (13)C-NMR and comparison with literature values. This study showed the anti-inflammatory activity of EtEx, the hexane (HexL) and dichloromethane (DichL) layers, and lupeol and betulin.